-
Je něco špatně v tomto záznamu ?
Negative prognostic impact of PD-L1 expression in tumor cells of undifferentiated (anaplastic) carcinoma with osteoclast-like giant cells of the pancreas: study of 13 cases comparing ductal pancreatic carcinoma and review of the literature
J. Hrudka, K. Lawrie, P. Waldauf, V. Ciprová, J. Moravcová, R. Matěj,
Jazyk angličtina Země Německo
Typ dokumentu srovnávací studie, časopisecké články, přehledy
Grantová podpora
VFN64165
Ministerstvo Zdravotnictví Ceské Republiky
TN64190
Ministerstvo Zdravotnictví Ceské Republiky
Research Laboratory of Tumor Diseases, CZ.2.16/3.1.00/24509
Ministerstvo Zdravotnictví Ceské Republiky
PROGRES Q28 Oncology
Univerzita Karlova v Praze
NLK
ProQuest Central
od 2003-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2011-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest)
od 2003-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2003-01-01 do Před 1 rokem
- MeSH
- antigeny CD274 analýza MeSH
- buněčná diferenciace * MeSH
- dospělí MeSH
- duktální karcinom slinivky břišní imunologie mortalita patologie terapie MeSH
- imunohistochemie MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádorové biomarkery analýza MeSH
- nádory slinivky břišní imunologie mortalita patologie terapie MeSH
- obrovské buňky imunologie patologie MeSH
- osteoklasty imunologie patologie MeSH
- prediktivní hodnota testů MeSH
- prognóza MeSH
- retrospektivní studie MeSH
- rizikové faktory MeSH
- senioři MeSH
- tumor infiltrující lymfocyty imunologie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- srovnávací studie MeSH
Pancreatic carcinoma remains one of the leading cancer-related causes of death worldwide and is generally characterized by a dismal prognosis and limited potential for oncologic treatment. A rare subvariant of pancreatic cancer, undifferentiated carcinoma with osteoclast-like giant cells (UCOGC), has an unpredictable prognosis according to many previous studies, with unexpectedly long survival in individual cases. In this study, we collected, retrospectively, 13 cases of well-documented UCOGCs and performed immunohistochemistry focused on the expression of the programmed death-ligand 1 (PD-L1) and several other potential therapeutic and predictive markers (PanTRK, p53, MSH2, PMS2, and the number of tumor-infiltrating lymphocytes), to explore their correlation with the follow-up of the patients. As a control group, we examined 24 cases of conventional pancreatic ductal adenocarcinoma (PDAC). In our results, PanTRK was negative in all 24 cases. P53 did not show any significant differences between UCOGCs and PDACs, and the entire cohort was MSH2, MLH1, PMS2, and MSH6 positive. Significant differences were present in the analysis of PD-L1: UCOGCs were found to express PD-L1 significantly more frequently and have a higher number of tumor-infiltrating lymphocytes than PDAC. The expression of PD-L1 was related to significantly shorter survival in patients with UCOGC and in the entire cohort. Patients with PD-L1 negative UCOGCs displayed surprisingly long survival in comparison to PD-L1 positive UCOGCs and PDACs (both PD-L1+ and PD-L1-). We compared our results with previously published data, and, after statistical analysis, we were able to identify PD-L1 as an effective prognostic marker of UCOGC and suggest a strong need for a clinical trial of immune checkpoint immunotherapy in patients with advanced PD-L1 positive UCOGC.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20027707
- 003
- CZ-PrNML
- 005
- 20210114152241.0
- 007
- ta
- 008
- 210105s2020 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00428-020-02830-8 $2 doi
- 035 __
- $a (PubMed)32424767
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Hrudka, Jan $u Department of Pathology, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, Prague, Czech Republic. jan.hrudka@lf3.cuni.cz.
- 245 10
- $a Negative prognostic impact of PD-L1 expression in tumor cells of undifferentiated (anaplastic) carcinoma with osteoclast-like giant cells of the pancreas: study of 13 cases comparing ductal pancreatic carcinoma and review of the literature / $c J. Hrudka, K. Lawrie, P. Waldauf, V. Ciprová, J. Moravcová, R. Matěj,
- 520 9_
- $a Pancreatic carcinoma remains one of the leading cancer-related causes of death worldwide and is generally characterized by a dismal prognosis and limited potential for oncologic treatment. A rare subvariant of pancreatic cancer, undifferentiated carcinoma with osteoclast-like giant cells (UCOGC), has an unpredictable prognosis according to many previous studies, with unexpectedly long survival in individual cases. In this study, we collected, retrospectively, 13 cases of well-documented UCOGCs and performed immunohistochemistry focused on the expression of the programmed death-ligand 1 (PD-L1) and several other potential therapeutic and predictive markers (PanTRK, p53, MSH2, PMS2, and the number of tumor-infiltrating lymphocytes), to explore their correlation with the follow-up of the patients. As a control group, we examined 24 cases of conventional pancreatic ductal adenocarcinoma (PDAC). In our results, PanTRK was negative in all 24 cases. P53 did not show any significant differences between UCOGCs and PDACs, and the entire cohort was MSH2, MLH1, PMS2, and MSH6 positive. Significant differences were present in the analysis of PD-L1: UCOGCs were found to express PD-L1 significantly more frequently and have a higher number of tumor-infiltrating lymphocytes than PDAC. The expression of PD-L1 was related to significantly shorter survival in patients with UCOGC and in the entire cohort. Patients with PD-L1 negative UCOGCs displayed surprisingly long survival in comparison to PD-L1 positive UCOGCs and PDACs (both PD-L1+ and PD-L1-). We compared our results with previously published data, and, after statistical analysis, we were able to identify PD-L1 as an effective prognostic marker of UCOGC and suggest a strong need for a clinical trial of immune checkpoint immunotherapy in patients with advanced PD-L1 positive UCOGC.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a antigeny CD274 $x analýza $7 D060890
- 650 _2
- $a nádorové biomarkery $x analýza $7 D014408
- 650 _2
- $a duktální karcinom slinivky břišní $x imunologie $x mortalita $x patologie $x terapie $7 D021441
- 650 12
- $a buněčná diferenciace $7 D002454
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a obrovské buňky $x imunologie $x patologie $7 D015726
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunohistochemie $7 D007150
- 650 _2
- $a tumor infiltrující lymfocyty $x imunologie $7 D016246
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a osteoklasty $x imunologie $x patologie $7 D010010
- 650 _2
- $a nádory slinivky břišní $x imunologie $x mortalita $x patologie $x terapie $7 D010190
- 650 _2
- $a prediktivní hodnota testů $7 D011237
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a rizikové faktory $7 D012307
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Lawrie, Kateřina $u Department of General Surgery, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, Prague, Czech Republic.
- 700 1_
- $a Waldauf, Petr $u Department of Anesthesiology and Intensive Care, 3rd Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Prague, Czech Republic.
- 700 1_
- $a Ciprová, Vanda $u Institute of Pathology, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
- 700 1_
- $a Moravcová, Jana $u Department of Pathology, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, Prague, Czech Republic. Clinical and Transplant Pathology Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Matěj, Radoslav $u Department of Pathology, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, Prague, Czech Republic. Institute of Pathology, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. Department of Pathology and Molecular Medicine, 3rd Faculty of Medicine, Charles University, Thomayer Hospital, Prague, Czech Republic.
- 773 0_
- $w MED00004660 $t Virchows Archiv : an international journal of pathology $x 1432-2307 $g Roč. 477, č. 5 (2020), s. 687-696
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32424767 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114152239 $b ABA008
- 999 __
- $a ok $b bmc $g 1608042 $s 1118887
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 477 $c 5 $d 687-696 $e 20200518 $i 1432-2307 $m Virchows Archiv $n Virchows Arch $x MED00004660
- GRA __
- $a VFN64165 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a TN64190 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a Research Laboratory of Tumor Diseases, CZ.2.16/3.1.00/24509 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a PROGRES Q28 Oncology $p Univerzita Karlova v Praze
- LZP __
- $a Pubmed-20210105
